Read from this company’s own annual reports filed with the SEC, not from a data vendor.
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $389.13M | $204.83M |
| 2024 | $290.52M | $89.16M |
| 2023 | $50.7M | $10.93M |
7 more years, included withMeasure
Capital expenditure
Figures onMeasure
Financial statements
Measure opens the income statement, balance sheet and cash flow for all 10 years and 39 quarters: every figure the company filed, plus the ratio charts built from them.
Free, no card, and it does not expire. See what the paid plans add
Total assets
Figures onMeasure
Derived from SEC XBRL filings. Not investment advice.
Also filed under Biotechnology, ranked by how closely they sit beside KRYS.
The assistant answers from what KRYS has actually filed: 10 annual reports filed with the SEC, 13F positions from the 1 tracked investor who hold it and 5 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.
Pressing one answers it here, from KRYS's filings and figures. One a day without an account; a free account has its own, and no card.
See every filed year for KRYS, quarter by quarter.
Ten seconds, no card, and nothing to cancel.
Total liabilities
Figures onMeasure
Shareholder equity
Figures onMeasure
Cash
Figures onMeasure
Current assets
Figures onMeasure
Current liabilities
Figures onMeasure
See all 10 filed years, not just 3
Every annual statement KRYS has ever filed, so a trend is measured over the whole record instead of a recent slice of it.
The full historyMeasure
Catch a turn before the year confirms it
Revenue, margins and cash flow quarter by quarter, where a change in direction shows up first.
Quarterly statementsMeasure
Ask why a number moved, get the filing back
Why a margin moved, where the cash went: answered from KRYS's own statements, not a guess.
Free, no card, and it does not expire.